Search results for "OVARIAN CANCER"

showing 10 items of 206 documents

Primary Epithelial Ovarian Neoplasms: New Concepts Concerning Origin, Pathogenesis and Classification Based on Morphology, Immunomarkers, Molecular F…

2011

The World Health Organization (WHO) classification of ovarian tumors, which first appeared in 1983 and since then has undergone a number of revisions, is based on morphologic features as well as on the concept that each category of ovarian tumors develops from a specific ovarian cell. According to this histogenetic classification, all the epithelial ovarian neoplasms are derived from the ovarian surface epithelium and/or from ovarian inclusion cysts, which are lined by the above epithelial cells. In recent years, a new approach to morphologic data, increasing presumptive evidence that the cell of origin of most, if not all, ovarian epithelial tumors may be extraovarian, especially from fall…

endocrine systemPathologymedicine.medical_specialtyendocrine system diseasesSerous carcinomaMedicine (all)Cell of originDiseaseBiologymedicine.diseasefemale genital diseases and pregnancy complicationsTherapeutic approachOvarian tumormedicine.anatomical_structureClear cell carcinomamedicineOvarian cancerFallopian tube
researchProduct

Interplay Between MicroRNAs and Oxidative Stress in Ovarian Conditions with a Focus on Ovarian Cancer and Endometriosis

2019

Ovarian cancer and endometriosis are two distinct gynaecological conditions that share many biological aspects incuding proliferation, invasion of surrounding tissue, inflammation, inhibition of apoptosis, deregulation of angiogenesis and the ability to spread at a distance. miRNAs are small non-coding RNAs (19–22 nt) that act as post-transcriptional modulators of gene expression and are involved in several of the aforementioned processes. In addition, a growing body of evidence supports the contribution of oxidative stress (OS) to these gynaecological diseases: increased peritoneal OS due to the decomposition of retrograde menstruation blood facilitates both endometriotic lesion developmen…

endometriosis0301 basic medicineAngiogenesisEndometriosisInflammationReviewCatalysisendometriosis-associated ovarian cancerMalignant transformationlcsh:ChemistryInorganic Chemistry03 medical and health sciences0302 clinical medicinehigh-grade serous ovarian cancermicroRNAmedicineAnimalsHumansRNA NeoplasmEpithelial–mesenchymal transitionPhysical and Theoretical ChemistryCàncerlcsh:QH301-705.5Molecular BiologySpectroscopyOvarian Neoplasmsbusiness.industryOrganic ChemistrychemoresistanceGeneral Medicinemedicine.diseaseComputer Science ApplicationsMicroRNAsOxidative Stress030104 developmental biologymedicine.anatomical_structurelcsh:Biology (General)lcsh:QD1-999Ginecologia030220 oncology & carcinogenesismiRNAsCancer researchFemaleepithelial-to-mesenchymal transitionmedicine.symptombusinessOvarian cancerFallopian tubeInternational Journal of Molecular Sciences
researchProduct

Inhibition of KIF20A by BKS0349 reduces endometriotic lesions in a xenograft mouse model

2019

AbstractSeveral studies have suggested a possible etiological association between ovarian endometriosis and ovarian cancer. Evidence has shown that KIF20A overexpression might confer a malignant phenotype to ovarian tumors by promoting proliferation and inhibiting apoptosis. However, no data about the role of KIF20A in endometriosis have been described. In this study, the human endometrium (n = 4) was transfected by mCherry adenovirus and intraperitoneally implanted in mice. Subsequently, mice were divided in three groups (n = 8/group) that were treated with Vehicle, BKS0349 (KIF20A-antagonist) or cabergoline (dopamine receptor agonist) for 21 days. mCherry-labeled endometriotic lesions wer…

endometriosisEmbryologyCabergolineEndometriosisEndometriosisKinesinsMice NudeApoptosisBiologyPeritoneal DiseasesEndometriumAndrologyEndometriumMiceGeneticsmedicineAnimalsHumansKIF20AMolecular BiologyCell ProliferationTUNEL assayOptical ImagingapoptosisObstetrics and GynecologyCell BiologyCell cyclemedicine.diseaseDisease Models Animalcell proliferationmedicine.anatomical_structureReproductive MedicineApoptosisOvarian EndometriosisHeterograftsImmunohistochemistrycell cycleFemaleOvarian cancerDevelopmental BiologyMolecular Human Reproduction
researchProduct

Properties and functions of myeloperoxidase and its role in ovarian cancer

2022

Background: Elevated levels of myeloperoxidase in body fluids are increasingly being used as an indicator for the diagnosis of cancer. Aim of the study: The aim of this study was to review the literature on the physical and chemical properties of myeloperoxidase, its role in carcinogenesis, the role of tumor-associated neutrophils in cancer, and the role of myeloperoxidase in ovarian cancer. Material and methods: The research literature published between January 1999 and December 2019 was reviewed. The properties and role of myeloperoxidase in the development of ovarian cancer were selected from publications available in selected online databases, including MEDLINE, PubMed, Scopus, and Web …

functionsrole of myeloperoxidaseovarian cancerneutrophilscarcinogenesiselevated levels of myeloperoxidaseMedical Science Pulse
researchProduct

BRCA1/BRCA2 genes mutational screening in Sicilian breast and/or ovarian cancer families.

2007

hereditary breast/ovarian cancer
researchProduct

Invasive ovarian seromucinous carcinoma developed on an endometrioma. The determining role of transvaginal ultrasound

2021

Endometriosis is a chronic inflammatory disease that has been associated with an increased risk of ovarian cancer, especially epithelial tumors. Transvaginal ultrasound is a first-line diagnostic method for the assessment of endometriosis, and of endometriomas, the ovarian cystic form of endometriosis. Endometriomas usually have typical ultrasound features that allow them to be easily diagnosed. When atypical images are observed, such as solid areas with vascular flow, their malignancy should be ruled out, especially in peri-menopausal women. Early diagnosis of these tumors is essential because immediate surgical treatment is crucial for prognosis. Malignant neoplasms associated with endome…

medicine.medical_specialty030219 obstetrics & reproductive medicinebusiness.industryUltrasoundEndometriosisObstetrics and GynecologyMalignancymedicine.disease03 medical and health sciences0302 clinical medicineReproductive Medicine030220 oncology & carcinogenesisOvarian carcinomamedicineRadiologyStage (cooking)businessOvarian cancerOvarian Seromucinous CarcinomaClear cellClínica e Investigación en Ginecología y Obstetricia
researchProduct

A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?

2012

Abstract Background Ovarian cancer (OC) is the sixth most common cancer in women. Currently, carboplatin/paclitaxel ± bevacizumab is the cornerstone of front-line treatment. Conversely, the therapeutic options for recurrent or progressive disease are not well defined. For platinum-sensitive patients the best therapeutic approach is still a re-challenge with a platinum-based regimen. Pegylated liposomal doxorubicin (PLD), is considered one of the most active therapeutic options for recurrent or progressive OC. In this retrospective mono-institutional analysis, we evaluated the impact of PLD on the outcome of OC patients. Patients and methods We performed the retrospective study on a cohort o…

medicine.medical_specialtyBevacizumabUrologySecond line treatmentchemistry.chemical_compoundOvarian cancerPegylated liposomal doxorubicinObstetrics and GynaecologymedicineStage (cooking)Systemic chemotherapyGynecologyPlatinum refractory patientsbusiness.industryResearchObstetrics and GynecologyCancerRetrospective cohort studymedicine.diseaseCarboplatinRegimenenzymes and coenzymes (carbohydrates)OncologychemistryPlatinum refractory patientlipids (amino acids peptides and proteins)Ovarian cancerbusinessProgressive diseasemedicine.drugJournal of ovarian research
researchProduct

2015

Summary Background The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. We report the final overall survival results of the trial. Methods ICON7 was an international, phase 3, open-label, randomised trial undertaken at 263 centres in 11 countries across Europe, Canada, Australia and New Zealand. Eligible adult women with newly diagnosed ovarian cancer that was either high-risk early-stage disease (International Federation of Gynecology and Obstetrics [FIGO] stage I–IIa, grade 3 or clear cell histology) or more adv…

medicine.medical_specialtyBevacizumabbusiness.industrymedicine.diseaseChemotherapy regimenCarboplatinlaw.inventionSurgerychemistry.chemical_compoundOncologyRandomized controlled trialchemistryMaintenance therapylawInternal medicineClinical endpointMedicinebusinessOvarian cancerSurvival analysismedicine.drugThe Lancet Oncology
researchProduct

Laparoscopic laterally extended pelvic resection for gynecological malignancies

2020

Lateral isolated gynecological cancer infiltrating the pelvic side wall has been considered non-operable with a poor oncological outcome.[1][1] The development of the laterally extended endopelvic resection and surgical progress for disease, overcoming the endopelvic fascia infiltrating muscles and

medicine.medical_specialtyCystadenocarcinomaLaparoscopesResection03 medical and health sciencesGynecologic Surgical Procedures0302 clinical medicinelaparoscopeGynecologic Surgical ProcedurelocalmedicineHumansAgedEndopelvic fasciaOvarian Neoplasms030219 obstetrics & reproductive medicineneoplasm recurrence localbusiness.industrySerousObstetrics and Gynecologyneoplasm recurrencemedicine.diseaseGynecological cancerCystadenocarcinoma SerousSurgerybody regionsCystadenocarcinoma SeroulaparoscopesSettore MED/40 - GINECOLOGIA E OSTETRICIAovarian cancerOncology030220 oncology & carcinogenesisFemaleLaparoscopybusinessOvarian cancer
researchProduct

European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking sur…

2021

The European Society of Gynaecological Oncology (ESGO) developed and established for the first time in 2016, and updated in 2020, quality indicators for advanced ovarian cancer surgery to audit and improve clinical practice in Europe and beyond. As a sequela of the continuous effort to improve oncologic care in patients with ovarian cancer, ESGO issued in 2018 a consensus guidance jointly with the European Society of Medical Oncology addressing in a multidisciplinary fashion 20 selected key questions in the management of ovarian cancer, ranging from molecular pathology to palliation in primary and relapse disease. In order to complement the above achievements and consolidate the promoted sy…

medicine.medical_specialtyEvidence-based practicebusiness.industryObstetrics and GynecologyCancerGuidelines as TopicPerioperativeDiseaseAuditCarcinoma Ovarian Epithelialmedicine.diseaseDebulkingSurgeryScientific evidenceEuropeovarian cancerSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologydebulking surgeryMedicineHumansFemalebusinessOvarian cancerPerioperative Period
researchProduct